LB Pharmaceuticals is a drug development company focused on development treatments for CNS disorders. The company's lead compound is LB-102; a novel benzamide being developed the treatment of schizophrenia owned and development internally by LB. LB-102 recently completed a Phase 1 study; a First-in-patient study is planned for July 2021.

Pharmaceutical

LB Pharmaceuticals

LB Pharmaceuticals' headquarters in New York, NY, United States

Zachary Prensky

Marc Panoff

Anna Eramo

Andrew Vaino

Robert Ruffolo

Ira D. Glick

Stefan Leucht

Herbert Y. Meltzer

John M. Kane

Christoph U. Correll

Description

People (1)

Zachary Prensky

Jobs